The Most Intuitive EDC Suite on the Market
Featuring superior usability and flexibility, TrialMaster® is the EDC solution for Phase I – IV clinical trials
It is well-proven that Patient Reported Outcomes are more accurate and reliable when recorded electronically rather than on paper. However, the solutions have historically required a separate mobile application that is costly and time-consuming to administer. Not anymore. Now it is possible for patients to enter their data directly into the EDC system, providing a simple, unified environment and immediate data access for the sponsor and site personnel.
During study design, the forms for use by patients are built alongside the other forms in the trial. Edit checks are programmed to test data validity and to set the expected time windows for data entry. For example, a patient diary form could be configured to accept data between 6 p.m. and midnight for every day between “Visit 2” and “Visit 3.”
A patient may then be registered to TrialMaster by the site coordinator. The details of that user registration are blinded to all sponsor personnel. The patient receives email notifications whenever data is expected, then clicks on a link in that email and enters the required password to log on. The patient is then presented with the forms expected in that time window, enters the data through simple web dialogs and is logged off automatically when the last form is completed. At this point, the data is immediately available in TrialMaster and appears automatically in the data exports.
In summary, TrialMaster provides the benefits of contemporaneous patient data, without the headache and expense of a separate ePRO system.
The TrialMaster Electronic Data Capture (EDC) solution makes it easier for doctors, nurses and other medical professionals to enter and manage their clinical trial data, thereby freeing up the maximum amount of time to care for patients. This ease of use for investigative sites, coupled with state-of-the-art risk-based monitoring (RBM) and analytical tools, means that life science companies can shorten the time to market for essential life-saving treatments.